Neuland Laboratories Limited Stock Price Today (NSE: NEULANDLAB)
Fundamental Score
Neuland Laboratories Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Neuland Laboratories Limited share price today is ₹22625.00, up +0.13% on NSE/BSE as of 16 September 2026. Neuland Laboratories Limited (NEULANDLAB) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹29.19K (Cr). The 52-week high for NEULANDLAB share price is ₹24225.00 and the 52-week low is ₹11500.00. At a P/E ratio of 58.32x, NEULANDLAB is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 21.42% and a debt-to-equity ratio of 0.10.
Neuland Laboratories Limited Share Price Chart — NSE/BSE Historical Performance
Neuland Laboratories Limited share price chart: 8.01% return over the past month. 52-week high ₹24225.00, 52-week low ₹11500.00.
Neuland Laboratories Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹22595.00 | ₹23125.00 | ₹21855.00 | ₹22625.00 | 50.78K (Cr) | |
| ₹23430.00 | ₹23480.00 | ₹22430.00 | ₹22595.00 | 54.67K (Cr) | |
| ₹23780.00 | ₹23895.00 | ₹23225.00 | ₹23535.00 | 43.90K (Cr) | |
| ₹23265.00 | ₹24150.00 | ₹23235.00 | ₹23800.00 | 55.26K (Cr) | |
| ₹24000.00 | ₹24225.00 | ₹23000.00 | ₹23195.00 | 57.98K (Cr) | |
| ₹23010.00 | ₹24100.00 | ₹23010.00 | ₹23995.00 | 82.21K (Cr) | |
| ₹22565.00 | ₹22960.00 | ₹22415.00 | ₹22870.00 | 22.29K (Cr) | |
| ₹23095.00 | ₹23095.00 | ₹22550.00 | ₹22660.00 | 21.11K (Cr) | |
| ₹23075.00 | ₹23295.00 | ₹22810.00 | ₹22890.00 | 32.65K (Cr) | |
| ₹23045.00 | ₹23320.00 | ₹22880.00 | ₹22960.00 | 39.70K (Cr) |
Neuland Laboratories Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹23010.00 | ₹24225.00 | ₹21855.00 | ₹22625.00 | -1.67% | |
| ₹19149.00 | ₹23881.00 | ₹19005.00 | ₹23010.00 | +20.16% | |
| ₹18750.00 | ₹20089.00 | ₹18055.00 | ₹19043.00 | +1.56% | |
| ₹17102.00 | ₹18775.00 | ₹16401.00 | ₹18579.00 | +8.64% | |
| ₹15003.00 | ₹18305.00 | ₹15003.00 | ₹17088.00 | +13.90% | |
| ₹12250.00 | ₹15491.00 | ₹12060.00 | ₹15003.00 | +22.47% | |
| ₹12594.00 | ₹13150.00 | ₹11500.00 | ₹12027.00 | -4.50% | |
| ₹13538.00 | ₹14170.00 | ₹12552.00 | ₹12825.00 | -5.27% | |
| ₹15277.00 | ₹15490.00 | ₹12447.00 | ₹13251.00 | -13.26% | |
| ₹17288.00 | ₹17550.00 | ₹14840.00 | ₹15175.00 | -12.22% | |
| ₹16552.00 | ₹19747.00 | ₹16025.00 | ₹17288.00 | +4.45% | |
| ₹14700.00 | ₹16776.00 | ₹14670.00 | ₹16473.00 | +12.06% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Neuland Laboratories Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Neuland Laboratories Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of NEULANDLAB across key market metrics for learning purposes.
Positive Indicators
13 factors identified
Strong Return on Equity (21.42%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (26.08%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (24.14%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (962.40%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (119.15%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (16.64% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (35.18% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (35.18% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.10)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (21.42x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 2.45)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Strong Cash Generation (₹318.72 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Strong Institutional Confidence (FII+DII: 36.30%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Risk Factors
2 factors identified
Premium Valuation Risk (P/E: 58.32x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
High Price-to-Book Ratio (19.04x)
Observation: Trading at significant premium to book value.
Analysis: High P/B ratios may indicate overvaluation relative to asset base.
Neuland Laboratories Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Neuland Laboratories Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Neuland Laboratories LimitedNeuland Laborat...Selected✓ NEULANDLAB • 524558 | 68.3/100 | ₹22625.00₹22625 | ₹29187.38₹29187.38 | 58.32Average 58.3 Average | 21.42%Excellent 21.42% Excellent | 26.08%Excellent 26.08% Excellent | 0.10Excellent 0.1 Excellent | 35.18%Excellent 35.18% Excellent | 16.64%Excellent 16.64% Excellent | 0.18% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1876.50₹1877 | ₹450228.65₹450228.65 | 37.23Average 37.2 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9467.50₹9468 | ₹250888.75₹250888.75 | 85.90Average 85.9 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4939.50₹4940 | ₹167182.32₹167182.32 | 78.91Average 78.9 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1138.70₹1139 | ₹113642.26₹113642.26 | 25.38Average 25.4 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1371.90₹1372 | ₹110828.94₹110828.94 | 32.87Average 32.9 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1941.10₹1941 | ₹104867.93₹104867.93 | 95.81Average 95.8 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1683.00₹1683 | ₹96839.82₹96839.82 | 26.30Average 26.3 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.70₹2101 | ₹96054.51₹96054.51 | 17.36Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1144.50₹1145 | ₹95565.75₹95565.75 | 29.58Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2293.70₹2294 | ₹94729.81₹94729.81 | 46.35Average 46.3 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price450228.65 Cr
- Divi's Laboratories Limited share price250888.75 Cr
- Torrent Pharmaceuticals Limited share price167182.32 Cr
- Zydus Lifesciences Limited share price113642.26 Cr
- Cipla Limited share price110828.94 Cr
Neuland Laboratories Limited PE Ratio History
Historical price-to-earnings ratio for NEULANDLAB — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹202.74 | ₹15175.00 | 74.8x |
| FY 2024 | ₹233.89 | ₹13723.80 | 58.7x |
| FY 2023 | ₹127.45 | ₹5291.40 | 41.5x |
| FY 2022 | ₹49.74 | ₹1666.95 | 33.5x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Neuland Laboratories Limited Dividend History
Annual cash dividends paid by NEULANDLAB — dividend yield 0.18%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹17.96 Cr |
| FY 2024 | ₹12.83 Cr |
| FY 2023 | ₹6.41 Cr |
| FY 2022 | ₹3.85 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Neuland Laboratories Limited Quarterly Performance
Latest quarterly metrics for NEULANDLAB — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
119.15%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
962.40%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
16.64%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
35.18%
Compounded annual net profit growth over 5 years
Neuland Laboratories Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for NEULANDLAB — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Neuland Laboratories Limited Financial Statements
Annual income statement, balance sheet and cash flow for Neuland Laboratories Limited (NEULANDLAB) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Neuland Laboratories Limited
About NEULANDLAB (Neuland Laboratories Limited)
Neuland Laboratories Ltd is a dynamic pharmaceutical company dedicated to the synthesis and supply of high-quality Active Pharmaceutical Ingredients (APIs). With a global footprint... spanning India, Europe, the United States, and other international markets, Neuland stands as a reliable partner for pharmaceutical innovators. The company is deeply committed to advancing healthcare through the meticulous development and production of APIs, catering to diverse therapeutic areas. Focused on innovation and stringent quality control, Neuland leverages advanced technologies and a skilled workforce to meet the evolving needs of its clientele. By consistently adhering to the highest regulatory standards, Neuland ensures the safety and efficacy of its products, establishing itself as a trusted source of pharmaceutical solutions. Beyond its core API offerings, Neuland Laboratories also excels in providing specialized custom manufacturing solutions, designed to meet the unique requirements of its partners. This includes bespoke synthesis and development services, tailored to support pharmaceutical companies from early-stage research through commercial production. Furthermore, Neuland distinguishes itself with its specialized expertise in peptide synthesis, catering to the growing demand for peptide-based therapeutics. This commitment to innovation and comprehensive service offerings positions Neuland as a versatile and value-added partner in the pharmaceutical landscape, enabling it to support a wide range of drug development and manufacturing needs. Established in 1984 and headquartered in the vibrant pharmaceutical hub of Hyderabad, India, Neuland Laboratories boasts a rich heritage of pharmaceutical excellence. The company's strategic location enables it to leverage the region's skilled talent pool and robust infrastructure to deliver innovative and cost-effective solutions to its global customer base. With decades of experience in the pharmaceutical industry, Neuland has cultivated a deep understanding of market dynamics and customer needs, positioning itself as a reliable and forward-thinking partner. Neuland Laboratories continues to build upon its legacy of quality and innovation, striving to improve global healthcare through its commitment to API development and manufacturing.
Company Details
Key Leadership
NEULANDLAB Share Price: Frequently Asked Questions
What is the current share price of Neuland Laboratories Limited?
Neuland Laboratories Limited (NEULANDLAB) trades at ₹22625.00 on NSE and BSE. Market cap ₹29.19K (Cr). Educational data only.
What is the P/E ratio of Neuland Laboratories Limited?
Neuland Laboratories Limited has a P/E of 58.32x vs industry average 34.89x.
What is the Bull Run score for Neuland Laboratories Limited?
Neuland Laboratories Limited has a Bull Run score of 68.3/100 based on 25+ financial parameters.
Does Neuland Laboratories Limited pay dividends?
Neuland Laboratories Limited has a dividend yield of 0.18%. Past dividends don't guarantee future payments.
What is the ROE of Neuland Laboratories Limited?
Neuland Laboratories Limited has ROE of 21.42%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Neuland Laboratories Limited?
Neuland Laboratories Limited has debt-to-equity of 0.10.
Is Neuland Laboratories Limited a good investment?
Bull Run gives Neuland Laboratories Limited a score of 68.3/100. This is not investment advice — consult a SEBI-registered advisor.